DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
ND0612 is an investigational drug.
There have been 9 clinical trials for ND0612. The most recent clinical trial was a Phase 2 trial, which was initiated on August 27th 2019.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Michael J. Fox Foundation for Parkinson's Research, and Quotient Clinical.
There are two hundred and forty-nine US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for ND0612
|A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).||NeuroDerm Ltd.||Phase 3|
|A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations||NeuroDerm Ltd.||Phase 3|
|A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion||NeuroDerm Ltd.||Phase 2|
Top disease conditions for ND0612
Top clinical trial sponsors for ND0612
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ND0612||⤷ Try it Free||Dopa decarboxylase inhibitor compositions||NeuroDerm, Ltd. (Rehovot, IL)||⤷ Try it Free|
|ND0612||⤷ Try it Free||Human anti-IL-23 antibodies, compositions, methods and uses||Janssen Biotech, Inc. (Horsham, PA)||⤷ Try it Free|
|ND0612||⤷ Try it Free||Fibronectin type III domain based scaffold compositions, methods and uses||Janssen Biotech, Inc. (Horsham, PA)||⤷ Try it Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|ND0612||Australia||AU2015228369||2034-03-13||⤷ Try it Free|
|ND0612||Brazil||BR112016021034||2034-03-13||⤷ Try it Free|
|ND0612||Canada||CA2942244||2034-03-13||⤷ Try it Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|